medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2024, Number 1

<< Back Next >>

Rev Med UAS 2024; 14 (1)

Vaginal Infections: A Public Health Problem in Mexico

Medina-de la Cruz O, Romo-Báez AS, Torres-Marceleño R, Tovar-Barrientos LG, Barajas-Mendiola MA, Gallegos-García V, Martínez-Gurrión LA

Language: Spanish
References: 64
Page: 71-86
PDF size: 615.31 Kb.


ABSTRACT

Vaginal infections are the outcome of disturbance of the dynamic ecosystem between bacteria, archaea, fungi, viruses, and protozoa that are part of the vaginal microbiota, when the homeostasis is lost, vaginal dysbiosis occurs. Vulvovaginal candidiasis, trichomonia-sis, and bacterial vaginosis are the most common vaginal infections. Disturbance in the vaginal secretions and pH, inflammation, pruritus, erythema, and microscopic findings are relevant for the cytological diagnosis to establish specific treatments. Risk factors that induce the development of vaginal diseases are hormonal changes, vaginal pH, poor hygiene, tight clothes, and pelvic tissue injuries. The present work aims to describe the main causal agents, risk factors, clinical picture, and diagnosis of the most common of vaginal infections.


REFERENCES

  1. Konadu DG, Owusu-Ofori A, Yidana Z, Iddrisu OF, Adu-Gyasi D, Dosoo D, et al. Prevalence of vulvovaginal candidiasis, bac-terial vaginosis and trichomoniasis in preg-nant women attending antenatal clinic in the middle belt of Ghana. BMC Preg Child 2019;19:341.

  2. Bignoumba M, Moghoa KHM, Muandze-Nzambe JU, Kassa-Kassa RF, Mouanga-Ndzime Y, Gafou A, et al. Vaginal Infections; Etiologies in South-Eastern Gabon; An Overview. Int J Womens Health 2022;14:505-515.

  3. Jansåker F, Frimodt-Møller N, Li X, Sundquist K. Novel risk factors associated with common vaginal infections: a na-tionwide primary health care cohort study. Int J Infect Dis 2022;116:380-386.

  4. Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, et al. Temporal dyna-mics of the human vaginal microbiota. Sci Transl Med 2012;4(132):132ra52.

  5. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal micro-biome of reproductive-age women. Proc Natl Acad Sci 2011 15;108:4680-7.

  6. Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, et al. Diversity of vaginal microbiome and metabolome du-ring genital infections. Sci Rep 2019 ;9(1):14095.

  7. Gilbert GG, Donders EB, Dekeersmaecker A, Vereecken A, Van Bulck B, Spitz B. Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol 2000; (182): 4.

  8. Sánchez-Hernández JA, González-Belén L, Rojas-Valderrama K, Muñoz-Zurita G. Pre-valencia de Candida albicans y su relación con cambios en el pH vaginal. Aten Fam 2017;24(1):18-22.

  9. Tarry W, Fisher M, Shen S, Mawhinney M. Candida albicans: the estrogen target for va-ginal colonization. J Surg Res 2005;129(2):278-282.

  10. González-Pedraza A, Ortiz-Zaragoza C, Dá-vila-Mendoza R, Valencia-Gómez CM. Infec-ciones cervicovaginales más frecuentes: prevalencia y factores de riesgo. Rev Cuba Obstet Ginecol 2007;33(2).

  11. Fischer G, Bradford J. Vulvovaginal candi-diasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 2011;15(4):263-267.

  12. Dirección General de Epidemiología. Anua-rios de Morbilidad 1984-2022. Revisado el 8 de febrero de 2023, Disponible en: https://epidemiologia.salud.gob.mx/anua-rio/html/index.html

  13. Abdul-Aziz M, Mahdy MAK, Abdul-Ghani R, Alhilali NA, Al-Mujahed LKA, Alabsi SA, et al. Bacterial vaginosis, vulvovaginal candidiasis and trichomonal vaginitis among reproduc-tive-aged women seeking primary healthcare in Sana’a city, Yemen. BMC In-fect Dis 2019; 879.

  14. Martínez-Ibarra MR, Medina-de la Cruz O, Gallegos-García V. La microbiota vagi-nal y su relación en el desarrollo de neopla-sia intraepitelial cervica. Rev Mex Enf Card 2022; 29 (3).

  15. Machado A, Foschi C, Marangoni A. Vaginal dysbiosis and biofilms. Front Cell Infect Mi-crobiol 2022;12.

  16. Han Y, Liu Z, Chen T. Role of Vaginal Micro-biota Dysbiosis in Gynecological Diseasesand the Potential Interventions. Front Micro-biol 2021;12:643422.

  17. Wu S, Hugerth LW, Schuppe-Koistinen I, Du J. The right bug in the right place: opportuni-ties for bacterial vaginosis treatment. Npj Biofilms Microbiomes 2022;8(1):1-11.

  18. Khedkar R, Pajai S. Bacterial Vaginosis: A Comprehensive Narrative on the Etiology, Clinical Features, and Management Ap-proach. Cureus 14(11):e31314.

  19. Deese J, Pradhan S, Goetz H, Morrison C. Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. Open Access J Con-tracept 2018;9:91-112.

  20. Coughlin G, Secor M. Bacterial vaginosis: update on evidence-based care. Adv Nurse Pract 2010;18(1):41-44, 53.

  21. Cerca N. Addressing the challenges with bacterial vaginosis pharmacotherapy. Ex-pert Opin Pharmacother 2023;24(1):11-13.

  22. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis 2016;214.

  23. Hösükoğlu FG, Ekşi F, Erinmez M, Uğur MG. An Epidemiologic Analysis of Vulvovaginal Candidiasis and Antifungal Susceptibilities. Infect Microbes Dis 2022;4(3):131.

  24. Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, Bohbot JM, et al. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Front Cell Infect Microbiol 2022; 12:934353.

  25. Cetin M, Ocak S, Gungoren A, Ulvi Hakverdi A. Distribution of Candida species in women with vulvovaginal symptoms and their asso-ciation with different ages and contraceptive methods. Scand J Infect Dis 2007;39(6-7):584-588.

  26. Paterniti I, Casili G, Filippone A, Lanza M, Ardizzone A, Capra AP, et al. A New Ap-proach for the Treatment of Recurrent Vul-vovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo. J Fungi 2022;8(12):1251.

  27. Jiménez JC, Garro ÁRG, Trabado SJT. Ge-neralidades de la candidiasis vulvovaginal. Rev Medica Sinerg 2023;8(3):e924-e924.

  28. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Mana-gement of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infec Dis 2016; 62 (4): e50.

  29. Farr A, Effendy I, Frey TB, Hof H, Mayser P, Petricevic L, et al. Guideline: Vulvovaginal candidosis. Mycoses 2021 ;64(6):583-602.

  30. Velázquez-Hernández N, Sánchez-An-guiano LF, Lares-Bayona EF, Cisneros-Pé-rez V, Milla-Villeda RH, Arreola-Herrera FA, et al. Comparación de la utilidad diagnóstica entre la inspección visual con ácido acético y la citología cervical. Ginecol Obstet Mex 2010:7.

  31. Abraham E, Fairley CK, Denham I, Bradshaw CS, Farquharson RM, Vodstrcil LA, et al. Positivity and Risk Factors for Tri-chomonas vaginalis Among Women Atten-ding a Sexual Health Clinic in Melbourne,2006 to 2019. Sex Transm Dis 2022;49(11):762.

  32. Zhu X, Liu L, Yixi L, Yang Y, Zhang Y, Yang Z, et al. The prevalence and risk factors of Trichomonas vaginalis in Wuhan and the Ti-betan area, China: a two-center study. Para-sitol Res 2023;122(1):265-273.

  33. Divakaruni AK, Mahabir B, Orrett FA, Rao AS, Srikanth A, Chattu VK, et al. Prevalence, clinical features, and diagnosis of Trichomo-nas vaginalis among female STI clinic atten-dees in Trinidad. J Fam Med Prim Care 2018;7(5):1054.

  34. Cenkowski M, Wudel B, Poliquin V. Vaginal trichomoniasis. CMAJ Can Med Assoc J 2022;194(6):E217.

  35. Ambrozio CL, Nagel AS, Jeske S, Bragança GCM, Borsuk S, Villela MM. Trichomonas vaginalis: prevalence and risk factors for wo-men in southern brazil. Rev Inst Med Trop São Paulo 2016;58:61.

  36. Jasek E, Chow EP, Ong JJ, Bradshaw CS, Chen MY, Hocking JS, et al. Sexually Trans-mitted Infections in Melbourne, Australia from 1918 to 2016: nearly a century of data. Commun Dis Intell Q Rep 2017;41(3):E212-E222.

  37. Muzny CA, Van Gerwen OT, Legendre D. Secnidazole: a treatment for trichomoniasis in adolescents and adults. Expert Rev Anti Infect Ther 2022; 20:8, 1067-1076.

  38. Sim M, Logan S, Goh LH. Vaginal discharge: evaluation and management in primary care. Singapore Med J 2020;61(6):297.

  39. Amabebe E, Anumba DOC. Psychosocial Stress, Cortisol Levels, and Maintenance of Vaginal Health. Front Endocrinol 2018;9.

  40. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol 2017; 168 (10).

  41. Lin YP, Chen WC, Cheng CM, Shen CJ. Va-ginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis. Diagnostics 2021;11(11):1996.

  42. Amabebe E, Anumba DOC. The Vaginal Mi-croenvironment: The Physiologic Role of Lactobacilli. Front Med 2018;5:181.

  43. O’Hanlon DE, Moench TR, Cone RA. Vagi-nal pH and Microbicidal Lactic Acid When Lactobacilli Dominate the Microbiota. PLoS ONE 2013;8(11):e80074.

  44. O’Hanlon DE, Moench TR, Cone RA. In va-ginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis 2011;11:200.

  45. Miller EA, Beasley DE, Dunn RR and Archie EA (2016) Lactobacilli Dominance and Vagi-nal pH: Why Is the Human Vaginal Micro-biome Unique? Front. Microbiol. 7:1936.

  46. Buscemi L, Arechavala A, Negroni R. Study of acute vulvovaginitis in sexually active adult women, with special reference to can-didosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital. Rev Iberoam Micol 2004;21(4):177-181.

  47. Lahti E, Vuopala S, Kauppila A, Blanco G, Ruokonen A, Laatikainen T. Maturation ofvaginal and endometrial epithelium in post-menopausal breast cancer patients recei-ving long-term tamoxifen. Gynecol Oncol 1994;55(3 Pt 1):410-414.

  48. Smeekens SP, van de Veerdonk FL, Kull-berg BJ, Netea MG. Genetic susceptibility to Candida infections. EMBO Mol Med 2013;5(6):805-813.

  49. Muzny CA, Schwebke JR. Asymptomatic Bacterial Vaginosis: To Treat or Not to Treat? Curr Infect Dis Rep 2020;22(12):32.

  50. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific va-ginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74(1):14-22.

  51. Disha T, Haque F. Prevalence and Risk Fac-tors of Vulvovaginal Candidosis during Preg-nancy: A Review. Infect Dis Obstet Gynecol 2022:e6195712.

  52. Disha T, Haque F. Prevalence and Risk Fac-tors of Vulvovaginal Candidosis during Preg-nancy: A Review. Infect Dis Obstet Gynecol. 2022 Jul 20;2022:6195712.

  53. Felix TC, de Araújo LB, Röder DVD de B, Pedroso R dos S. Evaluation of Vulvovagini-tis and Hygiene Habits of Women Attended in Primary Health Care Units of the Family. Int J Womens Health 2020;12:49-57.

  54. Czerwinski BS. Variation in feminine hygiene practices as a function of age. J Obstet Gy-necol Neonatal Nurs JOGNN 2000;29(6):625-633.

  55. Michelin SR, Marchi JG, Hyeda IS, Heide-mann ITSB, Nitschke RG. Percepção dasmulheres sobre promoção da saúde durante a consulta de enfermagem. Ciênc Cuid Saúde 2015:901-909.

  56. Elegbe IA, Botu M. A preliminary study on dressing patterns and incidence of candidia-sis. Am J Public Health 1982;72(2):176-177.

  57. Moon SG, Kim SH, Lee HJ, Moon MH, Myung JS. Pelvic Fistulas Complicating Pel-vic Surgery or Diseases: Spectrum of Ima-ging Findings. Korean J Radiol 2001;2(2):97-104.

  58. Zeng X, Zhang Y, Zhang T, Xue Y, Xu H, An R. Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi’an: A Cross-Sectional Study. BioMed Res Int 2018;2018:9703754.

  59. Singh J, Mumford SL, Pollack AZ, et al. Tam-pon use, environmental chemicals and oxi-dative stress in the BioCycle study. Environ Health 2019;18(1):11.

  60. Hoffmann JN, You HM, Hedberg EC, Jordan JA, McClintock MK. Prevalence of bacterial vaginosis and Candida among postmeno-pausal women in the United States. J Geron-tol B Psychol Sci Soc Sci 2014;69:S205-14.

  61. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 2014 May;21(5):450-8.

  62. Maria C, Zahra R, Sara P. Prevalence of Cervical-Vaginal Infections in the Pap-Smear Samples in Iran. Glob J Health Sci 2014;6(1):201-206.

  63. Nokiani FA, Akbari H, Rezaei M, Madani H, Ale Agha ME. Cost--effectiveness of pap smear in Kermanshah, Iran. Asian Pac J Cancer Prev APJCP. 2008;9(1):107-110.

  64. Giuliano C, Patel CR, Kale-Pradhan PB. A Guide to Bacterial Culture Identification And Results Interpretation. P T 2019;44(4):192-200.




2020     |     www.medigraphic.com